Cellenkos recently announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 1b/ 2a clinical trial of CK0802 for the treatment of patients with steroid-refractory Graft-Versus-Host Disease (GVHD).

Steroid-refractory GVHD represents a critical unmet need in post-transplant care. While allogeneic stem cell transplants are curative for many blood cancers, the procedure carries the risk of GVHD—a condition where donor cytotoxic T cells "misfire," recognising the patient's healthy organs as foreign and launching a systemic attack. This typically manifests as severe skin rashes, debilitating diarrhea, and liver failure.

Current first-line treatment relies on high-dose intravenous steroids. However, steroids act as a "blunt instrument," suppressing the aggressive T cells while simultaneously depleting the healthy immune system, leaving patients vulnerable to life-threatening infections. In nearly 50 percent of cases, steroids fail to calm the immune attack. Currently available second-line therapies often struggle to provide lasting results, frequently hampered by severe immunosuppression and hematologic toxicities. Novel therapies are urgently needed.

Simrit Parmar, MD, MSCI, Founder, Cellenkos, and Faculty, Texas A&M, School of Engineering and Medicine (EnMed), said, “FDA clearance to advance CK0802 into a phase 1b/ 2a trial marks a hopeful step forward for patients facing the dire prognosis of steroid-refractory GVHD. CK0802 is uniquely qualified to function under intense inflammatory stress, resetting the patient's immune system, and de-escalating donor T-cell attack without the toxicities typically associated with broad-spectrum immunosuppression."